SAN DIEGO, March 28, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced the success of its subsidiary HempMeds® Brazil's Cannabis Symposium in Rio Grande do Sul, Brazil. The event was put on in partnership with the National Association of Cannabidiol Users (ANUC) from March 19-23 and was held in the cities of Canoas, Passo Fundo and Porto Alegre. There, Dr. Stuart Titus, CEO of Medical Marijuana, Inc., spoke about the benefits of cannabidiol (CBD) and also discussed upcoming potential research opportunities in Brazil.
During the symposium, the Lutheran University of Brazil (Ulbra) announced its intent to begin research to evaluate the use of CBD in patients with Parkinson's disease in partnership with Dr. Kelson James Almeida, neurologist and current technical director of the Integrated Rehabilitation Center (CEIR), according to Brazilian newspaper GaúchaZH. Medical Marijuana, Inc. agreed to provide the necessary materials for the course of the studies.
"Despite the prejudice, the humanitarian nature of CBD must be taken into account," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We want to encourage a discussion about the benefits of cannabis and increase access to CBD in Brazil. We are hopeful that the research conducted in partnership with the university will provide more information to the medical community and lessen the resistance to the use of cannabidiol."
Other medical experts and pioneers who spoke at the week-long event included Junior Gibelli, Director of Medical Affairs at HempMeds® Brazil, pediatric neurologist Dr. Luiz Fernando Fonseca, Dr. Alan Fröhlich, neurologist of the Service of Neurology and Neurosurgery and Dr. Daniel Lima Varela, Professor of Neurology at IMED and Coordinator at the Outpatient Clinic Hospital in São Vicente de Paulo, and Dr. Pablo Winckler, neurologist and specialist in diabetic neuropathy.
HempMeds® Brazil was the first company authorized by ANVISA to import a CBD-based product into Brazil for those suffering from various specific medical conditions.
For more information about last week's symposium, please follow @HempMedsBrasil on Facebook.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
About HempMeds® Brazil
HempMeds® Brazil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson's, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brazil works on additional approvals for other indications. About HempMeds® Brazil and all its products with natural hemp oil: www.hempmeds.com.br.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
View original content with multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-brazil-provides-cbd-for-university-study-in-brazil-300620694.html
SOURCE Medical Marijuana, Inc.